[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342296-105":59,"doc-detail-342296-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","noninvasive-immunotyping-and-immunotherapy-monitoring-of-lung-cancers-via-nuclear-imaging-of-lag-3-and-pd-l1","Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1","","Immunotherapy improves lung cancer survival, but efficacy is constrained by reliance on single biomarkers such as PD-L1 and by spatiotemporal heterogeneity. The study proposes combining lymphocyte activation gene-3 (LAG-3) with PD-L1 for immunotype identification and immunotherapy monitoring using nuclear imaging. 99mTc-HYNIC-LAG-3 and 99mTc-HYNIC-PD-L1 probes were synthesized and shown to bind specifically in vitro with high radiochemical purity. SPECT/CT imaging demonstrated tumor uptake across lung cancer models with correlation to ex vivo uptake and immunohistochemistry. Dual-index imaging distinguished four immunotypes and revealed LAG-3 upregulation in immunotherapy-resistant mice, supporting noninvasive forecasting and resistance insight.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/noninvasive-immunotyping-and-immunotherapy-monitoring-of-lung-cancers-via-nuclear-imaging-of-lag-3-and-pd-l1/342296/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/noninvasive-immunotyping-and-immunotherapy-monitoring-of-lung-cancers-via-nuclear-imaging-of-lag-3-and-pd-l1/342296.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PD-L1 alone insufficient for immunotherapy monitoring in lung cancer?","Question",{"text":112,"@type":113},"Overall response rates remain limited because clinical decisions rely heavily on PD-L1 as a solitary marker, and PD-L1 expression shows complex spatiotemporal heterogeneity. This reduces predictive accuracy for immunotherapy outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the LAG-3 and PD-L1 imaging probes prepared?",{"text":117,"@type":113},"The study synthesized 99mTc-HYNIC-LAG-3 and 99mTc-HYNIC-PD-L1 probes using anti-human LAG-3 and PD-L1 antibodies, respectively.",{"name":119,"@type":110,"acceptedAnswer":120},"What did dual-index SPECT/CT imaging enable in this research?",{"text":121,"@type":113},"Dual-index imaging quantified LAG-3 and PD-L1 simultaneously and successfully distinguished four immunotypes, and it also showed LAG-3 upregulation in immunotherapy-resistant humanized mice.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342296,1791129079,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","[www.advancedscience.com](www.advancedscience.com)  \nNoninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging ofLAG-3 and PD-L1  \nLishu Zhao, Jianxian Ge, Ruru Zhang, Hao Wang, Xinyue Liu, Kandi Xu, Yujin Liu, Wencheng Zhao, Wengang Zhang, Li Ye, Zhimin Chen, Jianfeng Zeng,* Yayi He,* and Mingyuan Gao  \nImmunotherapy has signiﬁcantly improved cancer patient survival, while its eﬃcacy remains limited due to the reliance on a single marker like PD-L1 as well as its spatiotemporal heterogeneity. To address this issue, combining lymphocyte activation gene-3 (LAG-3) with PD-L1 is proposed for identifying immunotypes and monitoring immunotherapy through nuclear imaging. In short, 99mTc-HYNIC-􀀂LAG-3 and 99mTc-HYNIC-􀀂PD-L1 probes are synthesized using anti-human LAG-3 and PD-L1 antibodies, respectively. With high radiochemical purity and in vitro stability, these probes are conﬁrmed to speciﬁcally bind to LAG-3 or PD-L1 in LAG3+ A549, LAG3 − A549, and H1975 cells. SPECT/CT imaging of both probes showed speciﬁc in vivo tumor uptake in multiple lung cancer models, with signiﬁcant linear correlation with ex vivo tumor uptake and immunohistochemical expression levels ofLAG-3/PD-L1. Based on this, dual-index imaging was performed to simultaneously quantify LAG-3 and PD-L1. SPECT/CT imaging of 99mTc-HYNIC-􀀂LAG-3 and  \n125 I-􀀂PD-L1 successfully distinguished four immunotypes. In addition, SPECT/CT imaging revealed LAG-3 upregulation in LLC-bearing LAG-3 humanized mice resistant to immunotherapy. In conclusion, this study demonstrates the feasibility of nuclear imaging ofLAG-3 and PD-L1 for both noninvasive immunotyping and immunotherapy monitoring, thus oﬀering novel perspectives on forecasting immunotherapy response, uncovering resistance mechanism, and optimizing combination treatment regimens.  \n1. Introduction  \nLung cancers exhibit the highest mortality rates worldwide. [1] Immunotherapy represented by programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors has revolutionized the treatment regimens for advanced lung cancers. [1b,2] However, the overall response rate remains far from satisfactory, primarily attributed to the exclusive reliance on PD-L1 as a solitary immunotherapy marker in clinical settings, as well as its complex spatiotemporal heterogeneity.[2a,3]  \nThe expression level of PD-L1 on tumor cells, determined through immunohistochemistry (IHC), serves as a cornerstone for choosing immune monotherapy or combination therapy in clinical practice. However, in various cancers, especially in lung cancers, multiple stimulatory and inhibitory molecules have been found to be coexpressed with PD-1/PD-L1, including lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin domain and mucin domain- 3, and cytotoxic T lymphocyte antigen 4 (CTLA-4) . [4] Integrating additional immune  \n checkpoints (ICPs) with PD-L1 to enhance  \nL. Zhao, H. Wang, X. Liu, K. Xu, Y. Liu, W. Zhao, W. Zhang, L. Ye, Z. Chen, Y. He  \nDepartment of Medical Oncology Shanghai Pulmonary Hospital  \nTongji University Medical School Cancer Institute School of Medicine  \nTongji University  \nNo 507 Zhengmin Road, Shanghai 200433, China  \nE-mail: [yayi.he@tongji.edu.cn](yayi.he@tongji.edu.cn)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202404231](https://doi.org/10.1002/advs.202404231)[ ](https://doi.org/10.1002/advs.202404231)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202404231  \nJ. Ge, R. Zhang, J. Zeng, M. Gao  \nCenter for Molecular Imaging and Nuclear Medicine State Key Laboratory of Radiation Medicine and Protection  \nSchool for Radiological and Interdisciplinary Sciences (RAD-X) Collaborat","cbCail7YMvattRKN","https://ap.wps.com/l/cbCail7YMvattRKN","pdf",5245762,12,"English","# Introduction\n## Clinical need for better biomarkers\n## Role of PD-L1 and limitations of single-marker assessment\n## Immune checkpoints beyond PD-L1 (LAG-3 focus)\n## Rationale for combined LAG-3 and PD-L1 imaging","[{\"question\":\"Why is PD-L1 alone insufficient for immunotherapy monitoring in lung cancer?\",\"answer\":\"Overall response rates remain limited because clinical decisions rely heavily on PD-L1 as a solitary marker, and PD-L1 expression shows complex spatiotemporal heterogeneity. This reduces predictive accuracy for immunotherapy outcomes.\"},{\"question\":\"How were the LAG-3 and PD-L1 imaging probes prepared?\",\"answer\":\"The study synthesized 99mTc-HYNIC-LAG-3 and 99mTc-HYNIC-PD-L1 probes using anti-human LAG-3 and PD-L1 antibodies, respectively.\"},{\"question\":\"What did dual-index SPECT/CT imaging enable in this research?\",\"answer\":\"Dual-index imaging quantified LAG-3 and PD-L1 simultaneously and successfully distinguished four immunotypes, and it also showed LAG-3 upregulation in immunotherapy-resistant humanized mice.\"}]","Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1 | PDF",1790046045,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb2824a1a50fdd68b03d76fc16c42509.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b56e66768696a3d354d90b8d1a0d652a.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1263fd2482cee8a137a4440b9d95a469.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bd31f5466685c0b4e0184382e0bb3d8.webp",980,1287]